Dr. Mary Claire Haver

You remember the New York Times article that recently came out.

It's because they're on a performance enhancing level of testosterone.

What do you do?

Do you leave her on it?

To be honest, yes.

And I know that that's against the guidelines and I'm putting this out there for the world.

But the truth is I talk about, you know, where we have the data, where we don't have the data.

I know the transgender literature very well.

So, but remember, they also have levels, you know.

Which is basically the safety data.

That's the safety data.

It's true.

And I want to include them in this conversation because we talk about testosterone for women, for sexual function, for, you know, in this idea of gender affirmation to feel more like themselves, to, you know, have all these benefits.

And yet we're trying to take it away from our transgender people right now.

And it feels like there's this, you know, like contradiction.

And the data that we have is from the transgender population.

And the cis patients are frustrated because it is FDA approved for the transgender patients, but not for them.

That is a very fair point.

And it should be, you know, it's not, well, I wouldn't say it's FDA approved for the transgender patients.

It's covered by insurance.